RecallDepth
Class II Terminated

JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA

Company
Boehringer Ingelheim Pharmaceuticals, Inc.
Recall Initiated
March 9, 2023
Posted
March 29, 2023
Recall Number
D-0468-2023
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
69,375 bottles
Firm Location
Ridgefield, CT, United States

Reason for Recall

Labeling: Label Mix-up

Distribution

Product was distributed nationwide within the United States and PR

Lot / Code Info

Lot #: a) and b) E61835, exp. date JUN 2025

More recalls by Boehringer Ingelheim Pharmaceuticals, Inc.

View all recalls by this company →

Other recent Class II Drug recalls